AbbVie in the UK

From drug discovery and clinical trials right the way through to regulatory approval and reimbursement, we aim to find new ways to address the most serious health issues, challenging conventional timelines to get medicines from the lab to patients in years, not decades.

We recognise the UK’s strength and talent in early science, as well as the contributions of scientific and healthcare professional partners who play a key role in helping us transform our cutting-edge science into medicines. We support the UK Government’s commitment to restore the UK’s standing as a global leader in life sciences and drive the adoption of innovation in the NHS and we stand ready to partner where we have expertise. 

Rethinking where, how, and by whom care is delivered – whilst also ensuring earlier access innovative medicines, are enablers of improved health outcomes and ensuring we have an NHS fit for the future. 

We focus on improving access to services and early intervention to elevate outcomes, prevent or delay disease progression and reduce demand pressures on acute healthcare services. We don’t do this alone. We collaborate with policy makers, patient organisations and healthcare systems to facilitate and evidence the value of new models of care in areas of high patient and system burden.

We believe that everyone, irrespective of who they are or where they live, should have an equal opportunity to access the medicines and care they need.

We seek to help reduce inequality of access by empowering people through education programmes that equip them, their families and caregivers with the knowledge and tools to have informed conversations with healthcare teams and together make decisions about their care.